Retatrutide (LY-3437943) is a triple-agonist peptide that activates GLP-1, GIP, and glucagon receptors, three pathways that regulate appetite, metabolism, and fat oxidation
Interestingly, these intermediate forms are often more reactive and potentially more harmful than the original toxin
The goal is not restriction for its own sake it is creating a caloric and macronutrient framework that supports fat loss while preserving lean muscle
Here is a framework for assessing any oral tirzepatide product you encounter
Semaglutide (Novo Nordisk A/S, Denmark) dose was calculated in nmol/kg based on daily body weight and administrated subcutaneously using an insulin syringe at a final volume of 5 mL/kg
We do not recommend stopping one and starting the other the next day